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Abstract
Intestinal inflammation induces alterations of the gut microbiota and promotes overgrowth of the enteric pathogen
Salmonella enterica by largely unknown mechanisms. Here, we identified a host factor involved in this process. Specifically,
the C-type lectin RegIIIb is strongly upregulated during mucosal infection and released into the gut lumen. In vitro, RegIIIb
kills diverse commensal gut bacteria but not Salmonella enterica subspecies I serovar Typhimurium (S. Typhimurium).
Protection of the pathogen was attributable to its specific cell envelope structure. Co-infection experiments with an
avirulent S. Typhimurium mutant and a RegIIIb-sensitive commensal E. coli strain demonstrated that feeding of RegIIIb was
sufficient for suppressing commensals in the absence of all other changes inflicted by mucosal disease. These data suggest
that RegIIIb production by the host can promote S. Typhimurium infection by eliminating inhibitory gut microbiota.
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Introduction
Diarrhea is an infectious disease that causes high mortality
worldwide, especially among children and the elderly [1].
Salmonella spp. infection is an important cause of gastroenteritis
and has been widely studied because of facile Salmonella spp.
genetics and excellent animal disease models [2,3,4]. Current
treatment relies mostly on water and electrolyte supplementation
as Salmonellosis is often self-limiting in humans [5]. Patients which
show septic Salmonellosis are treated with antibiotics, but the rise of
drug resistant Salmonella strains is a current problem in efficient
Salmonella spp. therapy [5,6].
The normal intestinal microbiota of mammals counteracts
infection by Salmonella spp. and other pathogens, a phenomenon
referred to as colonization resistance (CR) [7,8,9,10]. The
microbiota can impair Salmonella spp. by blocking adhesion sites,
production of inhibitory or toxic molecules, or stimulation of the
host’s immune system [11,12,13,14]. However, intestinal inflam-
mation can reduce CR by diminishing inhibitory microbiota and
changing its composition. As a result, inflammation promotes
high-level Salmonella enterica colonization and effective transmission
by prolonged fecal shedding [15,16,17,18,19,20]. Interestingly, gut
inflammation also enhances intestinal infection by other entero-
pathogenic bacteria such as Citrobacter rodentium, Vibrio cholerae or
Clostridium difficile [21,22,23].
The mechanism promoting inflammation-mediated overgrowth
of enteric pathogens is not fully understood. Inflammation could
alter intestinal nutrient availability (i.e. mucus-derived carbohy-
drates) in a way that increases pathogen growth but diminishes
resident microbiota (‘nutrient hypothesis’) [16,24]. Another reason
for S. Typhimurium overgrowth in an inflamed gut is the
production of tetrathionate from microbiota-derived H2S by the
inflamed host mucosa [24]. Tetrathionate allows Salmonella enterica
subspecies I serovar Typhimurium (S. Typhimurium) to perform a
respiratory metabolism, which confers an advantage in the
competition with the microbiota [24]. Alternatively, inflammation
induces immune effector mechanisms that kill resident microbiota
but not resistant pathogens (‘killing hypothesis’). Indeed, the
antimicrobial protein lipocalin-2, which is upregulated in inflamed
mice and Rhesus macaques [25], blocks iron uptake in enteric
bacteria by sequestering enterochelin. However, S. Typhimurium
produces salmochelin, a glycosylated form of enterobactin, which
is not bound by lipocalin-2 [26,27]. Hence, S. Typhimurium gains
a selective advantage in the presence of lipocalin-2 [25]. These
data suggest that there is not a single factor leading to S.
Typhimurium outcompetition of the microbiota but more likely a
whole range of parameters playing a role in inflammation.
Antimicrobial peptides (e.g., defensins, cathelicidins) constitute
another host defence supporting the mucosal barrier. The C-type
lectin RegIIIc, a member of the Reg gene family, a diverse group
of secreted proteins harboring a C-type lectin carbohydrate
recognition domain, has been shown to exert antimicrobial effects
on commensal bacteria [28]. The closely related RegIIIb has
previously been shown to be upregulated in response to
inflammation and infections [29,30]. Here, we studied the
properties and in vivo relevance of the C-type lectin RegIIIb in
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inflammation-induced microbiota-pathogen competition. This was
of interest as RegIII family members are known to affect host-
commensal and host-pathogen interactions in the intestine
[28,30,31]. Our results imply that RegIIIb is indeed one of the
host factors explaining why S. Typhimurium can benefit from
triggering gut inflammation.
Materials and Methods
Ethics statement
All animals were handled in strict accordance with good animal
practice and all animal work was approved by local animal care
and use committees (license 04/862 Niedersa¨chsisches Landesamt
fu¨r Verbraucherschutz und Lebensmittelsicherheit; license 201/
2007 Kantonales Veterina¨ramt Zu¨rich).
Bacterial strains and growth conditions
All S. Typhimurium strains used in this study were derivatives of
SL1344 hisG rpsL xyl [32] (TABLE 1). The virulent and avirulent S.
Typhimurium strains have been described previously [33,34] as
well as S. Typhimurium DaroA [35]. Salmonella Typhimurium
mutants with defined gene deletions were obtained using the
Lambda phage red recombinase method [36] with primers
described at http://falkow.stanford.edu/whatwedo/wanner/ (see
also TABLE 2). For comparison of LPS defect mutants, Salmonella
Typhimurium LT galE [37] was used.
Non-pathogenic Escherichia coli E2 (stx12 stx22 eaeA2 hlyA2
espP2 katP2 astA2 recA+ tolC+) was isolated from BALB/c mice
originally obtained from Charles River and maintained at the
Hannover Medical School Animal Facility for 12 weeks.
Streptomycin- and rifampicin-resistant E2 derivatives were
obtained by consecutive selection of spontaneous mutants on
media containing rising antibiotic concentrations. Bacillus subtilis
168 was obtained from the Bacillus Genetic Stock Center. For
detailed description of gut commensal strains see TABLE 1.
For mouse infections, bacterial strains were grown for 12 h at
37uC in Luria-Bertani (LB) broth (0.3 M NaCl) and subcultured
for 4 h, as described [34].
Purification of recombinant Proteins
A synthetic sequence optimized for expression of murine RegIIIb
(ProteinID: NP_035166.1) without signal peptide in E. coli was
constructed (GENEART, Regensburg) and cloned into pET11a
(Novagen, Bad Soden). Variant RegIIIb R135T was constructed
using PCR mutagenesis and verified by sequencing. RegIIIb and
the variant were expressed in E. coli BL21 (DE3) and purified
essentially as described [38]. In brief, cells were induced with
0.1 mM IPTG for 3 h. Cells were harvested by centrifugation,
washed with PBS, and frozen at 220uC. Cells were thawed on ice
and resuspended in IB buffer (20 mM Tris–HCl, 10 mM EDTA,
1% Triton X-100, 0.1 mg/ml Lysozyme, pH 7.5). Cells were lysed
by sonication (7620 s pulses) and RegIIIb inclusion bodies were
sedimented by centrifugation. The pellet was resuspended in 25 ml
IB buffer and sonification/centrifugation was repeated three times
to reduce contaminations by intact cells. Purified inclusion bodies
were resuspended in denaturing buffer (7 M Guanidine–HCl,
0.15 M reduced glutathione, 2 mM EDTA, 0.1 M Tris–HCl,
pH 8.0). Still insoluble material was removed by centrifugation and
Table 1. Strains used in this study.
Strain Genetic information Strain information Growth condition Reference Figure
S. Typhimurium wt Wild type SL1344 virulent S. Typhimurium LB medium [33] Fig. 1, Fig. 2, Fig. S1
S. Typhimurium avir DinvG, sseD::aphT avirulent S. Typhimurium LB medium [34] Fig. 1, Fig. 5 Fig. S1
S. Typhimurium avir invG::Cm, ssrB::Km avirulent S. Typhimurium LB medium This study Fig. 4
S. Typhimurium DphoP phoP::Km LB medium This study Fig. 3
S. Typhimurium Drfc DaroA, rfc::Km LB medium This study Fig. 3
S. Typhimurium DrfbP DaroA, rfbP::Km LB medium This study Fig. 3
S. Typhimurium DgalE DgalE LT2 LB medium [37] Fig. 3
S. Typhimurium DrfaG DaroA, rfaG::Km LB medium This study Fig. 3
S. Typhimurium DpagL DaroA, pagL::Km LB medium This study Fig. 3
S. Typhimurium DpagP DaroA, pagP::Km LB medium This study Fig. 3
E. coli E2 Mouse intestinal isolate, selected for
spontaneous Rifampicin resistance
LB medium This study Fig. 2, Fig. 3
E. coli Nissle 1917 Probiotic E. coli LB medium [64] Fig. 3B
E. coli CFT073 Uropathogenic E. coli LB medium [65] Fig. 3B
B. subtilis 168 Bacillus Genetic
Stock Center
Fig. 3A
L. reuteri RRRif Mouse intestinal isolate, selected for
spontaneous Rifampicin resistance
MRS medium, grown
anaerobically, 37uC
[15] Fig. 3B
L. murinus RRRif Mouse intestinal isolate, selected for
spontaneous Rifampicin resistance
MRS medium, grown
anaerobically, 37uC
This study Fig. 3B
E. faecalis Mouse intestinal isolate MRS medium, grown
anaerobically, 37uC
This study Fig. 3B
C. butyricum DSM10702 Mouse intestinal isolate Wilkins Chalgren agar
supplemented with 5%
defibrillated sheep blood
(Oxoid), grown anaerobically
DSMZ, Braunschweig,
Germany
Fig. 3B
doi:10.1371/journal.pone.0020749.t001
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the supernatant was slowly diluted into ice-cold refolding buffer
(0.5 m arginine–HCl, 0.6 mM oxidized glutathione, 50 mM Tris–
HCl, pH 8.0). After overnight incubation, insoluble material was
removed by centrifugation and the supernatant was concentrated
using ultrafiltration with a 10 kDa cut-off membrane (Millipore).
The concentrate was dialyzed twice against binding buffer (25 mM
MES-NaOH, 25 mM NaCl, pH 6.0). Insoluble material was
removed by centrifugation. The final material was homogenous as
judged by SDS-PAGE. We verified by omitting lysozyme in the
purification protocol that it doesn’t contribute to bacterial killing in
the in vitro assays.
For some experiments, RegIIIb was trypsinated with 500 ng/ml
Trypsin (5000 NF-U mg-1) at a concentration of 50 mg ml21 in
binding buffer at 37uC for 2 h. For fluorescence detection,
RegIIIb was covalently linked to Alexa647 (Molecular Probes)
following the manufacturer’s instructions.
Purification of RegIIIc has been performed as described
previously [38].
Animal experiments
Mice were purchased from Charles River (Sulzfeld, Germany) or
bred at the RCHCI ETH Zurich, Switzerland. Eight to 12 weeks
old female BALB/c or C57BL/6 mice were pre-treated with 20 mg
streptomycin and 24 h later intragastrically infected with
56107 CFU of S. Typhimurium, as previously described [39].
For some experiments, streptomycin-pretreated MyD882/2
and MyD88+/2 mice (C57BL/6 background [40]) were infected
with wild-type S. Typhimurium and sacrificed 24 h later.
Colonization was determined by plating feces on selective media
(MacConkey agar with appropriate antibiotics). In contrast to
many non-culturable commensals, the gut luminal cfu data of S.
Typhimurium (and E. coli) obtained by plating always match the
cfu data obtained in feces. This is well documented by data from
plating, 16S RT PCR, in situ hybridization and immunofluores-
cence microscopy [9,15,39,60].
To determine the effect of RegIIIb on bacterial colonization,
mice received a single intragastric dose, or daily doses of 80 mg
RegIIIb or 80 mg BSA respectively, in 200 ml binding buffer.
In vitro assays
Binding and cidal activities of RegIIIb were determined using
bacteria from late log liquid cultures. Bacteria were washed and
resuspended in binding buffer (25 mM MES-NaOH, 25 mM
NaCl, pH 6.0) at a density of 106 CFU ml21. RegIIIb was added
at various concentrations and the mixture was incubated for
various times at 37uC. Bacteria were then plated either on LB,
Wilkins Chalgren, or MRS agar, and grown under aerobic or
anaerobic conditions (7% H2, 10% CO2, 83% N2). As controls
( = 100% survival) Bacteria incubated with binding buffer only,
were analyzed.
In some experiments, RegIIIb was pre-incubated for 10 min
with a fivefold (weight/weigth) excess of peptidoglycan (insoluble
PGN from Bacillus subtilis, Sigma) before addition to bacterial
suspensions. Peptidoglycan co-precipitation was determined as
described [28].
Bacteria were incubated for 40 min at 4uC with 1 mM
fluorescence-labeled RegIIIb in binding buffer containing 1%
bovine serum albumin to minimize unspecific binding. At this low
concentration, no cidal effect of RegIIIb that could potentially
affect the results has been detected. Bacteria were washed three
times in binding buffer and analyzed using a Calibur flow
cytometer (BD Biosciences).
Antibody generation, WB, and immunohistochemistry
A polyclonal rabbit anti-RegIIIb antibody was produced by
Neosystem (Strasbourg, France) using recombinant RegIIIb. The
antibody was further affinity purified with AminoLink Kit
(Thermo Scientific Pierce) using recombinant RegIIIb. The
antibody is specific for RegIIIb (Fig. S1).
For analysis of intestinal RegIIIb, cecal contents were
resuspended in PBS. Proteins were separated by SDS-PAGE
followed by Western blotting using the polyclonal anti-RegIIIb
antibody and chemoluminescent detection (GE Healthcare).
For immunohistochemistry, cecal tissue samples were fixed
overnight in PBS with 4% paraformaldehyde at 4uC, incubated in
20% sucrose at 4uC for one day, and snap frozen in O.C.T.
compound (Sakura). Cryosections (10 mm) were air dried,
permeabilized with 0.1% Triton in PBS, blocked (10% goat
serum in PBS), and stained with rabbit anti-RegIIIb antibody and
cy3-labelled anti-rabbit antibody (Jackson). No tissue staining was
observed with secondary antibody only. Nuclei were visualized
with DAPI. The actin brush border was stained with Phalloidin-
Alexa 647 (Fluoprobes). Images were taken with a Axiovert 200
(Carl Zeiss, Inc.) microscope, an Ultraview confocal head
Table 2. Primers used in this study.
Primer Sequences
rfbP::Km rfbP-P1 (60 nt) 59-ATT TTA TTT ACA TTA TGC ACG GTC AGA GGG TGA GGA TTA AGT GTA GGC TGG AGC TGC TTC-39
rfbP-P4 (60 nt) 59-GCT AAT TTA TAC AAT TAT TAT TCA GTA CTT CTC GGT AAG CAT TCC GGG GAT CCG TCG ACC-39
rfbP-F (20 nt) 59-ACC TGA GTT ACG CTG CTA TG-39
rfbP-R (19 nt) 59-TCC TGT CAG GTG TGG AAA C-39
rfaG::Km rfaG-P1 (60 nt) 59-TGC CGC ATG AGG CAC GCA CCA TAG ATT TGG ACA GCC TGC TGT GTA GGC TGG AGC TGC TTC-39
rfaG-P4 (60 nt) 59-ATC TTT ACC GCG CCA TAG TGT GGT TAA CGG CGC TTT CAG CAT TCC GGG GAT CCG TCG ACC-39
rfaG-F (19 nt) 59-CCG GCT GAA GAT GTT ATC G-39
rfaG-R (20 nt) 59-GCG TCT CCA GCT CTC TGA AC-39
pagL::Km pagL-P1 (60 nt) 59-GCC GGT TAA AAA TAA CTA TTG ACA TTG AAA TGG TGG TGG AGT GTA GGC TGG AGC TGC TTC-39
pagL-P4 (60 nt) 59-TTA CTC CTT CAG CCA GCA ACT CGC TAA TTG TTA TTC AAC TAT TCC GGG GAT CCG TCG ACC-39
pagL-F (20 nt) 59-TGC TAT ATC AGC CGT TTC TG-39
pagL-R (20 nt) 59-CTG ATT GGA CAT CTT TCC TG-39
pagP::Km pagP-P1 (60 nt) 59-GGT TAA TGT TGT TAT TAT CAC AGT CGA ATT TTT GAA CGG TGT GTA GGC TGG AGC TGC TTC-39
pagP-P4 (60 nt) 59-TAA GAC TTT TTA ATT CAC AAC TGA AGC ATA CCC TTC CCC AAT TCC GGG GAT CCG TCG ACC-39
pagP-F (20 nt) 59-ACG CCG TTA ACC CGA TAC TC-39
pagP-R (20 nt) 59-ACG TCT TTG CTG CCA TCT TC-39
doi:10.1371/journal.pone.0020749.t002
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(PerkinElmer), and a krypton argon laser (643-RYB-A01; Melles
Griot). Infrared, red and green fluorescence was recorded
confocally, and blue fluorescence was recorded by epifluorescence
microscopy.
Quantitative RT-PCR
RegIIIb mRNA levels were quantified using QIAGEN isolation
kits, M-MLV reverse Transcriptase RNase H Minus, the
QuantiTect SYBR Green PCR kit (Qiagen), and primers as
described below. ct values were normalized to GAPDH [41] and
represent the median of triplicate analyses compared to non-
infected mice. Cycling parameters were 94uC (15 s), 60uC (30 s),
72uC (30 s) in a RotorGene 3000 cycler (Corbett Research,
Cambridgeshire, UK). The following Primers were used: GAPDH
(59-GGC TGC CCA GAA CAT CAT CCC TGC AT-39 and 59-
ACG TCA GAT CCA CGA CGG ACA CAT TGG-39) and
RegIIIb (59- CTG CCT TAG ACC GTG CTT TC-39 and 59-
ATA GGG CAA CTT CAC CTC AC-39).
Statistical analysis
Statistical analysis was performed using the Student T-Test
except for long-term colonization where the Mann Whitney U-test
was applied. P # 0.05 was considered to be statistically significant.
Results
S. Typhimurium infection induces intestinal RegIIIb
expression
The C-type lectin RegIIIb is highly induced in rat intestinal tissues
during enteric Salmonellosis [42,43]. We aimed at analyzing the role of
RegIIIb in microbiota-pathogen competition in the streptomycin-
treated mouse model for S. Typhimurium induced gut inflammation.
To initially confirm validity of previous data for this model, we
performed quantitative real time PCR of RegIIIb mRNA on cecal
tissue (Fig. 1A). Mice infected with an avirulent S. Typhimurium strain
that fails to cause intestinal inflammation, show slightly upregulated
RegIIIb mRNA levels compared to baseline levels in non-infected
control mice. In contrast, mice infected with wild-type S.Typhimurium
(wt) show drastically increased levels (,10-fold; Fig. 1A).
To confirm qPCR data on protein level, we analyzed intestinal
contents in Western blots using an affinity-purified polyclonal
antibody to RegIIIb (Fig. S2A). This antibody recognizes a major
15 kDa band and a weaker band of approx. 14 kDa, which likely
correspond to RegIIIb and a proteolytically processed form
(Fig. 1B). Proteolytic cleavage by trypsin has been reported for the
closely related C-type lectin RegIIIc [28]. As trypsin is present in
intestinal contents, RegIIIb processing is likely to occur in vivo.
Quantification using purified recombinant RegIIIb as a
reference indicated that RegIIIb was present at baseline levels of
less than 1 mg/g intestinal contents in uninfected mice, but
increased to levels of some 350 mg/g in mice infected with virulent
S. Typhimurium (Fig. S2B).
S. Typhimurium-induced RegIIIb upregulation critically de-
pended on the innate immunity adapter protein MyD88 (Fig. 1B)
as previously reported in case of RegIIIb induction by the
commensal microbiota [44]. The same is true for the closely
related C-type lectin RegIIIc in a L. monocytogenes infection model
[30]. Immunohistochemistry of intestinal tissue sections revealed
weak RegIIIb levels in S. Typhimurium infected mice, which were
non-inflamed, but prominent RegIIIb expression in intestinal
epithelial cells in mice with gut inflammation (Fig. 1C). These data
confirmed and extended previous observations of RegIIIb
upregulation in intestinal tissues in response to virulent Salmonella
spp..
RegIIIb kills commensal bacteria but not S. Typhimurium
The C-type lectin RegIIIc has been reported to have bactericidal
effects. To monitor the antimicrobial activity of closely related
RegIIIb on different bacterial species, we produced recombinant
RegIIIb. We tested its antibacterial spectrum in in vitro killing assays
Figure 1. S. Typhimurium-induced RegIIIb expression in mouse
intestine. A) RegIIIb expression was analyzed in the cecum of
streptomycin-treated C57BL/6 mice infected for 24 h with S. Typhimur-
ium wt and S. Typhimurium avir, respectively. Expression was analyzed
by quantitative real time PCR normalized to GAPDH mRNA levels (fold
expression versus unmanipulated mouse). B) Western Blot of intestinal
contents obtained from S. Typhimurium infected MyD88+/2 and
MyD882/2 litter mates 24 h post infection using a polyclonal antibody
to RegIIIb. Samples 1–3 were obtained from infected MyD88+/2 mice
and samples 4–6 from MyD882/2 litter mates. C) Immunohistochem-
istry of the cecal mucosa of S. Typhimurium infected mice 24 h post
infection (grey, nuclei (DAPI); blue, actin (phalloidin); red, RegIIIb). Scale
bar: 10 mm.
doi:10.1371/journal.pone.0020749.g001
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against S.Typhimuriumwt, E. coli and B. subtilis. B. subtilis and E. coli
were chosen as these strains were used in other studies assessing
bacterial susceptibility to RegIIIc [28]. Since Bacillus spp. is not a
normal member of the GI tract, several other Gram+ bacteria
typical for the GI tract were also included in the analysis
(Lactobacillus spp., Enterococcus spp., Clostridium spp.). Aliquots of
bacterial suspensions were incubated with recombinant RegIIIb
and bacterial survival was analyzed after 30 minutes. The cfu of the
negative control (no RegIIIb) was taken as 100% survival rate.
Interestingly, recombinant purified RegIIIb had bactericidal
activity against E. coli but not S. Typhimurium and B. subtilis. We
tested an extended panel of commensal gut bacteria but found no
clear killing preference for Gram+ vs. Gram2 species (Fig. 2A, B).
The related intestinal C-type lectin, RegIIIc is known to selectively
kill Gram+ bacteria [28]. These data suggested that the two lectins
may have complementary antibacterial profiles. Effective doses for
bactericidal activity were below 2.5 mM (Fig. 2A, Fig. S2B), which is
in the range of the RegIIIb concentrations observed in the S.
Typhimurium-infected intestine (see above). Since S. Typhimurium
was found to be resistant to RegIIIb, we hypothesized that S.
Typhimurium-induced RegIIIb could thus affect some commensal
microorganisms in the intestinal lumen upon gut inflammation, and
thereby contribute to the substantial ecological changes in gut
microbiota and observed pathogen overgrowth during S. Typhi-
murium wt infection [15,19,45].
Molecular structure correlates with bactericidal activity
To identify the mechanisms of S. Typhimurium resistance to
RegIIIb we decided to determine the molecular target of RegIIIb on
the bacterial cell envelope. An excess of peptidoglycan (PGN)
completely blocked RegIIIb bactericidal activity (data not shown)
consistent with the previously reported role of PGN as RegIIIb target
[46]. Although RegIIIb did bind to bacteria containing various PGN
types, including S. Typhimurium in vivo (data not shown), bactericidal
activity was preferentially directed against particular PGN types.
Specifically, some sensitive bacteria carried the negatively charged
amino acid residue diaminopimelic acid at position 3 of the PGN
pentapeptide (PGN-DAP: E. coli, Clostridium butyricum), whereas most
resistant bacteria carried a neutral or positively charged amino acid at
this position (B. subtilis, amidated diaminopimelic acid; Lactobacillus casei,
L. murinus andEnterococcus faecalis, lysine) [47,48,49]. Interestingly, loop 2
of RegIIIb, which is homologous to the usual C-type lectin binding site
but apparently not involved in binding the carbohydrate portion of
peptidoglycan [46], contains a positively charged arginine (R135),
while the equivalent residue is a threonine in RegIIIc which kills
bacteria with PGN-Lys. In an unrelated insect peptidoglycan binding
protein PGRP-LE a similar arginine - threonine substitution controls
selective activity against PGN-DAP vs. PGN-LYS [50]. To test the
hypothesis that arginine 135 of RegIIIb promotes selective cidal
interaction with negatively charged PGN, we generated a RegIIIb
R135T variant by site-directed mutagenesis. RegIIIb R135T had
weaker cidal activity against E. coli but gained cidal activity against B.
subtilis that was lacking in the wild-type protein (Fig. 2C) supporting the
role of amino acid 135 in selective interaction with certain PGN types.
The still moderate activity of RegIIIb R135T against B. subtilis
suggested multiple additional interactions as observed for other PGN-
binding proteins [51]. This was also evident from wild-type RegIIIb
resistance of Lactobacillus reuteri despite its Lys-type peptidoglycan.
The O-antigen protects S. Typhimurium against RegIIIb
killing
RegIIIb did not kill PGN-DAP containing S. Typhimurium but
did kill E. coli containing the same type of PGN (Fig. 2A). This
observation was consistent with the uncompromised viability of
Salmonella enterica isolated from infected gut contents [52]. As one
possible resistance mechanism, Salmonella spp. outer membrane
lipopolysaccharides (LPS) [53] could restrict access of RegIIIb to its
target peptidoglycan in the periplasm. To test this hypothesis, we
compared isogenic S. Typhimurium mutants with defined defects in
LPS biosynthesis. These mutants lacked the O-antigen polymerase
(rfc), the complete O-antigen (rfbP), the outer core and the O-
antigen (galE) and the inner core, outer core and the O-antigen
(rfaG) and certain lipid-A modifications (phoP, pagL and pagP)
(Fig. 3C). Shortening of the polysaccharide component of LPS
(Fig. 3A) progressively increased S. Typhimurium susceptibility to
RegIIIb-mediated killing (Fig. 3B) as observed for other antimicro-
bial molecules [54]. Moreover, PhoP-dependent expression of pagP
(involved in hepta-acetylation of lipid A with palmitate [55]) but not
pagL (catalyzes the 3-O-deacylation of lipid A at position 3 [56]) was
essential for S. Typhimurium resistance to RegIIIb (Fig. 3B). These
data suggested that in wild-type S. Typhimurium carrying a rigid
LPS layer, RegIIIb had limited access to peptidoglycan and
therefore weak anti - S. Typhimurium activity. Interestingly, E. coli
has similar LPS modification capabilities, but under our experimen-
tal in vitro conditions, these mechanisms were apparently insufficient
to mediate resistance against RegIIIb in various E. coli strains.
RegIIIb selectively suppresses E. coli in a simple
co-colonization model
The in vitro data suggested that RegIIIb killed various bacterial
species but not S. Typhimurium. S. Typhimurium-induced
RegIIIb could thus contribute to ecological changes in gut
microbiota during S. Typhimurium infection [15,19,45]. To test
this hypothesis, we established a simple experimental mouse model
employing intestinal colonization of streptomycin-pretreated mice
[39] with S. Typhimurium and a molecularly defined (see Material
& Methods sections) non-pathogenic, streptomycin-resistant Esch-
erichia coli strain (E. coli E2) from our mouse colony. S.
Typhimurium colonization preferentially occurs in individuals
with high initial E. coli abundance [9], which suggests potential
relevance for S. Typhimurium/E. coli competition.
When given individually, both E. coli E2 and S. Typhimurium
colonized the mouse intestine at high levels in streptomycin-treated
mice (data not shown). Virulent S. Typhimurium induced intestinal
inflammation as previously reported, while an avirulent S. Typhimur-
ium invG ssrB strain as well as the E. coli E2 isolate did not induce
obvious pathology (data not shown) in agreement with previous reports
[15,39,57,58,59]. Interestingly, virulent S.Typhimuriumwt suppressed
co-administered E. coli E2 (Fig. 4A), while avirulent S. Typhimurium
permitted stable high level co-colonization of both species (Fig. 4B).
Our simple co-colonization model thus reproduced important aspects
of S. Typhimurium-induced commensal suppression.
To test whether the host factor RegIIIb might be sufficient for
E. coli E2 in vivo suppression, we administered recombinant
RegIIIb to mice co-colonized by E. coli E2 and avirulent S.
Typhimurium. A single dose of 80 mg RegIIIb (similar to
endogenous RegIIIb levels induced by virulent S. Typhimurium
wt, see above) administered at 5 h post infection rapidly
suppressed E. coli but did not affect S. Typhimurium gut
colonization (Fig. 4C). RegIIIb was thus sufficient for suppressing
commensal E. coli E2 even in the absence of all other mechanisms
that might further enhance this effect in the inflamed gut.
RegIIIb supports S. Typhimurium infection in the
presence of complex gut microbiota
A complex gut microbiota strongly inhibits S. Typhimurium gut
colonization [9,15]. Through induction of RegIIIb (Fig. 1A), S.
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Typhimurium might exploit the host to suppress competing
microbiota. To test this hypothesis, the simple E. coli/S.
Typhimurium co-colonization model in streptomycin-pretreated
mice was inappropriate. The competing microbiota is already
weakened in this model. Consequently, even avirulent S.
Typhimurium can efficiently colonize for several days even in
the absence of intestinal inflammation.
To test if RegIIIb-induction could offer S. Typhimurium any
benefit under more natural conditions, we tested conventional
mice containing a normal gut microbiota (no streptomycin
pretreatment). We determined the fecal density of facultative
aerobic bacteria in our mouse colony by plating (Fig. 5A). This
technique closely reflects the gut luminal bacterial counts based on
previous data from plating, 16S RT PCR, in situ hybridization
and immunofluorescence microscopy [9,15,39,60]. However, it is
important to notice that luminal (or fecal) counts do not necessarily
correlate with mucosal colonization levels. One group of mice was
orally treated with a single dose of BSA, the other group with
recombinant RegIIIb, both followed by an oral dose of S.
Typhimurium (56107 cfu, by gavage). BSA-treated mice did not
show efficient S. Typhimurium luminal colonization (Fig. 5A) as
observed previously [9,39,61]. However, oral treatment with a
single dose of RegIIIb suppressed endogenous Gram2 facultative
aerobic microbiota and enabled subsequent S. Typhimurium
luminal colonization at moderate levels (Fig. 5A).
In another model, we followed long-term shedding of S.
Typhimurium in streptomycin-pretreated mice during recoloniza-
tion with competing microbiota, which terminates pathogen
growth in the gut after approximately 4 days, in the absence of
mucosal inflammation [15,60]. Due to its defect to trigger
inflammation, the avirulent S. Typhimurium strain is overgrown
by the competing commensal flora. We aimed at testing if oral
supplementation of RegIIIb could interfere with reemerging
microbiota-induced colonization resistance. Indeed, daily RegIIIb
administration significantly prolonged S. Typhimurium fecal
shedding (Fig. 5B). The combined data showed that RegIIIb can
enhance S. Typhimurium gut luminal colonization in the presence
of complex commensal microbiota.
Discussion
S. Typhimurium induces a complex inflammatory response in
the intestinal mucosa. This inflammation has a profound impact
on gut microbiota composition. Among others, microbiota that
competes with S. Typhimurium is suppressed whereas S.
Typhimurium colonization is promoted. The molecular mecha-
nisms of this process are probably complex and poorly understood
[10]. On one side, altered nutrient availability in the inflamed gut
may lead to positive selection of the pathogen over the commensal
flora [16,24]. On the other side numerous host defense factors are
differentially regulated during intestinal inflammation [25,42,43,
62] and could mediate selective killing of the commensal
microbiota [17,20]. Their relevance for facilitating S. Typhimur-
ium colonization has remained unclear.
Among the host factors induced by S. Typhimurium, the C-
type lectin RegIIIb is particularly strongly upregulated. RegIIIb
can block mucosal infections with pathogenic Yersinia spp.
although it does not inhibit Yersinia spp. directly [31]. RegIIIb
is also highly related to another C-type lectin, RegIIIc that kills
Gram+ bacteria [28] and protects against mucosal Listeria
infections [30]. For these reasons, we studied the role of RegIIIb
in enteric salmonellosis.
We showed that S. Typhimurium infection induced elevated
RegIIIb protein levels in the intestine. Recombinant RegIIIb
bound peptidoglycan in vitro and killed a diverse set of both Gram2
and Gram+ bacteria but not S. Typhimurium. Site-directed
mutagenesis of RegIIIb and comparison of various S. Typhimur-
ium mutants suggested that peptidoglycan structure and lipopoly-
saccharide composition (for Gram2 bacteria) might explain the
bactericidal activity spectrum of RegIIIb. Recently published work
points out that HIP/PAP (hepatointestinal pancreatic/pancreatitis
associated protein), a human ortholog of RegIIIc interacts with the
Figure 2. RegIIIb has bactericidal activity against several Gram+ and Gram2 intestinal bacteria. A) Survival of S. Typhimurium (filled
circles), E. coli (open circles), and Bacillus subtilis (triangles) after 30 min incubation with various concentrations of RegIIIb. Means 6 SD of five
independent replicates are shown. B) Survival of various intestinal commensal bacteria after incubation with 10 mM RegIIIb (1, E. coli Nissle; 2, E. coli
CFT073; 3, Lactobacillus reuteri; 4, Lactobacillus murinus; 5, Enterococcus faecalis; 6, Clostridium butyricum). C) Bactericidal activities of 10 mM RegIIIb
and 10 mM RegIIIb R135T with altered putative binding site against S. Typhimurium, E. coli and B. subtilis (symbols as in A). Statistical significances for
deviation from results obtained for bacteria incubated with buffer only are shown.
doi:10.1371/journal.pone.0020749.g002
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carbohydrate moiety of peptidoglycan which may be also the case
for RegIIIb [46]. The observed antibacterial spectrum of RegIIIb
was clearly different from the reported spectrum of the closely
related RegIIIc suggesting that these two mucosal lectins might
serve complementary functions in modulation of gut microbiota.
We hypothesize that S. Typhimurium is protected against RegIIIb
dependent killing by specific modifications mediating a rigid LPS
layer. Possibly, differences between S. Typhimurium and E. coli in
PhoP-dependent regulatory circuits [63] and/or subtle differences
in LPS structure might affect the susceptibility for RegIIIb. Future
work will have to address the structural mechanisms underlying
differential RegIIIb killing of E. coli and S. Typhimurium.
Doses in the range of endogenous RegIIIb levels were orally
administered and could efficiently suppress E. coli gut colonization
and facilitate S. Typhimurium colonization. Our findings suggest
that RegIIIb may contribute to inflammation-induced suppression
of competing microbiota although we have no direct evidence of
RegIIIb playing a role in vivo. Experiments using RegIIIb ko mice
may aid clarifying this issue.
Presently, we do not know the exact effects of RegIIIb treatment
on microbiota composition and function. This might be an important
topic for future research. However, effects resulting from RegIIIb
feeding were moderate compared to the much stronger facilitation of
S. Typhimurium colonization in mice with acute intestinal
inflammation. Thus, additional host factors and bacterial fitness
factors apparently also contribute significantly to inflammation-
induced microbiota changes and pathogen overgrowth. Possible
candidates for these additional factors include the paralogue RegIIIc
with a complementary bactericidal spectrum, defensins and other yet
unidentified, Salmonella-encoded fitness factors. Further work will be
required to elucidate the respective relevance and the unknown
mechanisms, and how they might be integrated with the function of
the previously identified host and bacterial factors in the microbiota-
pathogen interplay in the inflamed intestine.
Figure 3. The O-antigen mediates S. Typhimurium resistance against RegIIIb. A) SDS-PAGE (silver stain) of lipopolysaccharide of wild-type S.
Typhimurium (lane 1) and mutants (phoP, rfc, rfbP, galE, rfaG). B) Bactericidal activity of 10 mM RegIIIb against various S. Typhimurium mutants.
Statistical significances for deviation from results obtained for wildtype bacteria are shown. C) Schematic representation of Salmonella spp. LPS-forms.
doi:10.1371/journal.pone.0020749.g003
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Figure 4. RegIIIb is sufficient to suppress E. coli during competitive growth in the non-inflamed gut. A) Colonization of streptomycin-
pretreated mice with virulent S. Typhimurium wt (filled circles) and non-pathogenic E. coli E2 (open circles). Virulent S. Typhimurium induces gut
inflammation and suppresses co-colonization with E. coli. B) Avirulent S. Typhimurium permits E. coli co-colonization. C) A single dose of RegIIIb is
sufficient to complement the suppression defect of avirulent S. Typhimurium. Each data point represents one mouse. Statistical significances for
deviation from results obtained at 5 h are shown.
doi:10.1371/journal.pone.0020749.g004
Figure 5. RegIIIb facilitates S. Typhimurium colonization in mice with complex microbiota. A) Colonization of mice with normal intestinal
microbiota (no streptomycin pre-treatment) with facultative aerobes (open circles, colonies on MacConkey agar plates; left). Colonization levels of
facultative aerobes after a single oral dose of BSA or RegIIIb and subsequent infection with S. Typhimurium (closed circles; middle and right). A single
dose of RegIIIb suppressed resident facultative aerobic bacteria and partially relieved colonization resistance against S. Typhimurium. Statistical
significances for deviation from results obtained with BSA alone are shown. B) RegIIIb facilitates prolonged gut colonization by avirulent S.
Typhimurium in streptomycin-pretreated mice. Daily RegIIIb doses (80 mg in 200 ml) prolonged S. Typhimurium colonization (filled down triangles)
compared to control mice that received bovine serum albumin (open up triangles). In panel A) one data point represents one mouse; in panel B) one
data point represents the median with SD of 5 mice. Statistical significances for deviation from results obtained for BSA alone are shown. Comparable
data were obtained in an independent experiment.
doi:10.1371/journal.pone.0020749.g005
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Supporting Information
Figure S1 RegIIIb levels in intestinal content of C57BL/
6 mice. A) Western Blot of mouse intestinal contents with a
purified polyclonal antiserum to RegIIIb. Samples 1–3 were
obtained from streptomycin-treated mice infected with S. Typhi-
murium avir whereas samples 4–6 were taken from mice infected
with virulent S. Typhimurium 1 day post infection. B) Western
Blot showing different dilutions of recombinant RegIIIb compared
to intestinal content (lane 6) of mouse infected with virulent S.
Typhimurium. (lane 1: 0.552 mg; lane 2: 0.276 mg; lane 3:
0.138 mg; lane 4: 0.069 mg; lane 5: 0.0345 mg; lane 6: 0.26 mg
of intestinal content). Lane 6 is equivalent to 92 ng of RegIIIb
(analysis via AlphaImager3400) which results in ,350 mg/g
RegIIIb.
(TIF)
Figure S2 Specificity of purified rabbit polyclonal
RegIIIb antibody. Western Blot with RegIIIb purified antise-
rum on same amounts of recombinant RegIIIb and recombinant
RegIIIc.
(TIF)
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